![](/img/cover-not-exists.png)
PCN45 PEMBROLIZUMAB PLUS AXITINIB (P+A) VERSUS OTHER FIRST-LINE (1L) SYSTEMIC THERAPIES FOR ADVANCED/METASTATIC CLEAR-CELL RENAL CELL CARCINOMA (CCMRCC) — A NETWORK META-ANALYSIS (NMA)
McGovern, I., Simon, A., Shirali, R., Zhong, Y., Perini, R., Lorenzi, M., Adejoro, O.Volume:
22
Journal:
Value in Health
DOI:
10.1016/j.jval.2019.09.242
Date:
November, 2019
File:
PDF, 381 KB
2019